On November 29, Qixiang Tengda announced that the first phase (100,000 tons/year) production line of the 200,000 tons/year nitrile latex project invested and constructed by the company was completed on November 11, 2020, and it was put into trial operation on November 17. . At present, the device process has been fully integrated and produced qualified products, achieving a successful start-up. The completion and commissioning of the first phase of the project will play an important role in the expansion of the company's nitrile latex production capacity, the improvement of equipment capacity utilization, and the extension of the industrial chain. At present, the second phase of the nitrile latex project (100,000 tons/year) has entered the equipment installation stage, and the construction progress is being fully promoted.
The next day, Qixiang Tengda issued an announcement stating that the company signed the "Strategic Cooperation Framework Agreement" with Blue Sail Medical on November 30, 2020. The two parties agreed that from December 1, 2020 to December 31, 2021, the company will sell no less than 30,000 tons of carboxyl nitrile latex to Lanfan Medical. The agreement can alleviate the impact of the company's nitrile latex production capacity release on the market, and at the same time will have a positive impact on the company's operating performance during the contract implementation year.
According to the announcement, after the outbreak this year, the global demand for nitrile gloves, etc. has surged. Lanfan Medical has invested in the construction of a health protection (new gloves) project with an annual output of 2 billion units, which has been completed and put into production, and plans to launch 30 billion units. /Year health protection (nitrile) gloves project, so the demand for nitrile latex, the raw material for nitrile gloves, has also increased significantly.
According to the framework agreement, from December 1 this year to the end of 2021, the carboxylated nitrile latex sold by Qixiang Tengda to Lanfan Medical will not be less than 30,000 tons; thereafter, the number of carboxylated nitrile latex cooperation between the two parties will be the previous one. Confirm before December of the year. Qi Xiang Tengda said that the signing of the "Strategic Cooperation Framework Agreement" with Blue Sail Medical can alleviate the impact of the company's nitrile latex production capacity release on the market, and at the same time, it will have a positive impact on the company's operating performance during the contract implementation year, which is beneficial to Enhancing the company's sustainable profitability is conducive to the company's long-term development.
